Rick A Vreman (Rick Vreman)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 24

Top Topics

Decision Making

Radical Prostatectomy

Top Venues

International journal of technology assessment in health care

International journal of environmental research and public health

Clinical pharmacology and therapeutics

PharmacoEconomics

This page only lists publications with an associated author ORCID identifier.

Publications

Jorge Madrid Paredes, Jan-Willem Versteeg, Rick A Vreman, Lourens T Bloem
Agreement about Availability of Alternative Treatments for Innovative Drugs Assessed by the EMA and HTA Organizations. Clinical pharmacology and therapeutics (2024)
Jorge Madrid Paredes, Jan-Willem Versteeg, Rick A Vreman, Lourens T Bloem
Agreement about Availability of Alternative Treatments for Innovative Drugs Assessed by the EMA and HTA Organizations. Clinical pharmacology and therapeutics 116 (1) (2024)
Milou Amber Hogervorst, Rick A Vreman, Inkatuuli Heikkinen, Indranil Bagchi, Iñaki Gutierrez-Ibarluzea, Bettina Ryll, Hans-Georg Eichler, Elena Petelos, Sean Tunis, Claudine Sapede, Wim G Goettsch, Rosanne Janssens, Isabelle Huys, Liese Barbier, Deirdre DeJean, Valentina Strammiello, Dimitra Lingri, Melinda Goodall, Magdalini Papadaki, Massoud Toussi, Despina Voulgaraki, Ania Mitan, Wija Oortwijn
UNCERTAINTY MANAGEMENT IN REGULATORY AND HEALTH TECHNOLOGY ASSESSMENT DECISION-MAKING ON DRUGS: GUIDANCE OF THE HTAi-DIA WORKING GROUP. International journal of technology assessment in health care (2023)
Milou Amber Hogervorst, Rick A Vreman, Inkatuuli Heikkinen, Wija Oortwijn
Response to uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working Group - author's reply. International journal of technology assessment in health care 40 (1) (2023)
Milou Amber Hogervorst, Rick A Vreman, Inkatuuli Heikkinen, Wija Oortwijn
RESPONSE TO UNCERTAINTY MANAGEMENT IN REGULATORY AND HEALTH TECHNOLOGY ASSESSMENT DECISION-MAKING ON DRUGS: GUIDANCE OF THE HTAi-DIA WORKING GROUP - AUTHOR'S REPLY. International journal of technology assessment in health care (2023)
Rick A Vreman, Daan van Hoof, Anna Nachtnebel, Joël Daems, Marc van de Casteele, Emer Fogarty, Roisin Adams, Lonneke Timmers
The Beneluxa Initiative Domain Task Force HTA: A Comparison of Member Countries' Past Health Technology Assessments. International journal of technology assessment in health care (2023)
Milou Amber Hogervorst, Rick A Vreman, Inkatuuli Heikkinen, Wija Oortwijn
Response to uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working Group - author's reply. International journal of technology assessment in health care 40 (1) (2023)
Milou Amber Hogervorst, Rick A Vreman, Inkatuuli Heikkinen, Wija Oortwijn
Response to uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working Group - author's reply. International journal of technology assessment in health care 40 (1) (2023)
Li Jiu, Milou A Hogervorst, Rick A Vreman, Aukje K Mantel-Teeuwisse, Wim G Goettsch
Understanding innovation of health technology assessment methods: the IHTAM framework. International journal of technology assessment in health care 38 (1) (2022)
Marcelien H E Callenbach, Rick A Vreman, Aukje K Mantel-Teeuwisse, Wim G Goettsch
When Reality Does Not Meet Expectations-Experiences and Perceived Attitudes of Dutch Stakeholders Regarding Payment and Reimbursement Models for High-Priced Hospital Drugs. International journal of environmental research and public health 20 (1) (2022)
Marcelien H E Callenbach, Rick A Vreman, Aukje K Mantel-Teeuwisse, Wim G Goettsch
When Reality Does Not Meet Expectations-Experiences and Perceived Attitudes of Dutch Stakeholders Regarding Payment and Reimbursement Models for High-Priced Hospital Drugs. International journal of environmental research and public health 20 (1) (2022)
Rick A Vreman, George Strigkos, Hubert G M Leufkens, Holger J Schünemann, Aukje K Mantel-Teeuwisse, Wim G Goettsch
Addressing uncertainty in relative effectiveness assessments by HTA organizations. International journal of technology assessment in health care 38 (1) (2022)
Marcelien H E Callenbach, Rick A Vreman, Aukje K Mantel-Teeuwisse, Wim G Goettsch
When Reality Does Not Meet Expectations-Experiences and Perceived Attitudes of Dutch Stakeholders Regarding Payment and Reimbursement Models for High-Priced Hospital Drugs. International journal of environmental research and public health 20 (1) (2022)
Marcelien H E Callenbach, Rick A Vreman, Aukje K Mantel-Teeuwisse, Wim G Goettsch
When Reality Does Not Meet Expectations-Experiences and Perceived Attitudes of Dutch Stakeholders Regarding Payment and Reimbursement Models for High-Priced Hospital Drugs. International journal of environmental research and public health 20 (1) (2022)
Hans-Georg Eichler, Roisin Adams, Einar Andreassen, Peter Arlett, Marc van de Casteele, Suzannah J Chapman, Wim G Goettsch, Jonathan Lind Martinsson, Jordi Llinares-Garcia, Anna Nachtnebel, Elias Pean, Guido Rasi, Tove Ragna Reksten, Lonneke Timmers, Rick A Vreman, Inneke van de Vijver, Martin Wenzl
Exploring the opportunities for alignment of regulatory postauthorization requirements and data required for performance-based managed entry agreements. International journal of technology assessment in health care 37 (1) (2021)
Rick A Vreman, Joost W Geenen, Saskia Knies, Aukje K Mantel-Teeuwisse, Hubert G M Leufkens, Wim G Goettsch
Comment on "Deterministic Sensitivity Analysis Under Ignorance". PharmacoEconomics 39 (10) (2021)
Rachel R J Kalf, Rick A Vreman, Diana M J Delnoij, M Marcel Bouvy, Wim G Goettsch
Bridging the gap: Can International Consortium of Health Outcomes Measurement standard sets align outcomes accepted for regulatory and health technology assessment decision-making of oncology medicines. Pharmacology research & perspectives 9 (2) (2021)
Rick A Vreman, Joost W Geenen, Anke M Hövels, Wim G Goettsch, Hubert G M Leufkens, Maiwenn J Al
Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia. Applied health economics and health policy 17 (6) (2020)
Rick A Vreman, Joost W Geenen, Saskia Knies, Aukje K Mantel-Teeuwisse, Hubert G M Leufkens, Wim G Goettsch
The Application and Implications of Novel Deterministic Sensitivity Analysis Methods. PharmacoEconomics 39 (1) (2020)
Joost W Geenen, Rick A Vreman, Cornelis Boersma, Olaf H Klungel, Anke M Hövels, Renske M T Ten Ham
Increasing the information provided by probabilistic sensitivity analysis: The relative density plot. Cost effectiveness and resource allocation : C/E 18 (1) (2020)
Rick A Vreman, Thomas F Broekhoff, Hubert Gm Leufkens, Aukje K Mantel-Teeuwisse, Wim G Goettsch
Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis. International journal of environmental research and public health 17 (22) (2020)
Rick A Vreman, Svetlana V Belitser, Ana T M Mota, Anke M Hövels, Wim G Goettsch, Kit C B Roes, Hubert G M Leufkens, Aukje K Mantel-Teeuwisse
Efficacy gap between phase II and subsequent phase III studies in oncology. British journal of clinical pharmacology 86 (7) (2020)
Rick A Vreman, Huseyin Naci, Wim G Goettsch, Aukje K Mantel-Teeuwisse, Sebastian G Schneeweiss, Hubertus G Leufkens, Aaron S Kesselheim
Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe. Clinical pharmacology and therapeutics 108 (2) (2020)
Rick A Vreman, Lourens T Bloem, Stijn van Oirschot, Jarno Hoekman, Menno E van der Elst, Hubert Gm Leufkens, Olaf H Klungel, Wim G Goettsch, Aukje K Mantel-Teeuwisse
The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs. International journal of health policy and management (2020)